Overview
Alternative Name Monorden
Lyophilized Powder yes
Origin Humicola fuscoatra.
Source Natural
MW: 364.78
Purity: >99%
Effective concentration 1-100 nM.
Structure
Chemical name (1aR,2Z,4E,14R,15aR)-8-Chloro-1a,14,15,15atetrahydro-9 ,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione.
Molecular formula C18H17ClO6.
CAS No.: 12772-57-5
Activity Radicicol is an antifungal antibiotic originally discovered to be a tyrosine kinase inhibitor1. The specific inhibition of the chaperone Hsp90 confers anticancer properties to Radicicol2,3. In addition, it also exhibits anti-angiogenic activity in vivo, and reduces the expression of VEGF4,5.
References-Activity
- Chanmugam, P. et al. (1995) J. Biol. Chem. 270, 5418.
- Schulte, T.W. et al. (1999) Mol. Endocrinol. 13, 1435.
- Soga, S. et al. (2003) Curr. Cancer Drug Targets 3, 359.
- Oikawa, T. et al. (1993) Eur. J. Pharmacol. 241, 221.
- Hur, E. et al. (2002) Mol. Pharmacol. 62, 975.
Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
Solubility DMSO, ethanol. Centrifuge all product preparations before use (10000 x g 5 min).
Storage of solutions Up to four weeks at 4°C or three months at -20°C.
Our bioassay
Alomone Labs Radicicol inhibits cell proliferation in various cell lines.HeLa (blue), WEHI (pink) or Jurkat (red) cells were grown in presence of different concentrations of Radicicol (#R-370) for 4 days. The number of live cells was measured by XTT cell proliferation assay kit, normalized to the control (100%) and plotted against the drug concentration.
References - Scientific background
- Chanmugam, P. et al. (1995) J. Biol. Chem. 270, 5418.
- Kwon, H.J. et al. (1992) Cancer Res. 52, 6926.
- Schulte, T.W. et al. (1999) Mol. Endocrinol. 13, 1435.
- Soga, S. et al. (2003) Curr. Cancer Drug Targets. 3, 359.
- Roe, S.M. et al. (1999) J. Med. Chem. 42, 260.
- Sharma, S.V. et al. (1998) Oncogene. 16, 2639.
- Zhao, J.F. et al. (1995) Oncogene. 11, 161.
- Soga, S. et al. (1998) J. Biol. Chem. 273, 822.
- Oikawa, T. et al. (1993) Eur. J. Pharmacol. 241, 221.
- Hur, E. et al. (2002) Mol. Pharmacol. 62, 975.
- Na, Y.J. et al. (2001) Int. Immunopharmacol. 1, 1877.
- Shimada, Y. et al. (1995) J. Antibiot (Tokyo). 48, 824.
Scientific background An antifungal macrocyclic antibiotic, originally recognized as a protein tyrosine kinase inhibitor. Radicicol inhibits p60v-src kinase activity, and tyrosine phosphorylation of p53/56lyn.1,2
The specific inhibition of the chaperone Hsp90 confers anticancer properties to Radicicol.3,4 In eukaryotic cells, Hsp90 catalyzes the final activation step of many regulatory proteins. Cells that lose Hsp90 function are severely compromised and cannot progress through the cell cycle.
Radicicol, similarly to Geldanamycin, binds to the nucleotide-binding pocket, and inhibits ATPase activity of Hsp90.5 This causes destabilization of Hsp90 client proteins (v-Src, Raf-1, ErbB2 Ras), many of which are essential for tumor cell growth.6 Oncogene induced transformation of NIH 3T3 cells (src, ras, and mos) is suppressed by radicicol and it also disrupts the K-Ras-activated signaling pathways by selective depletion of Raf kinase.7,8 In addition, it also exhibits anti-angiogenic activity in vivo, and reduces the expression of VEGF.9,10
Radicicol inhibits AP-1-, NF-kB- and serum response factor (SRF)-mediated transcription.11 It inhibits the expression of COX-2 without affecting COX-1 expression in LPS-stimulated macrophages,1 and induces the differentiation of HL-60 cells into macrophages, by blocking the cell cycle at G1 and G2 sites.12
The specific inhibition of the chaperone Hsp90 confers anticancer properties to Radicicol.3,4 In eukaryotic cells, Hsp90 catalyzes the final activation step of many regulatory proteins. Cells that lose Hsp90 function are severely compromised and cannot progress through the cell cycle.
Radicicol, similarly to Geldanamycin, binds to the nucleotide-binding pocket, and inhibits ATPase activity of Hsp90.5 This causes destabilization of Hsp90 client proteins (v-Src, Raf-1, ErbB2 Ras), many of which are essential for tumor cell growth.6 Oncogene induced transformation of NIH 3T3 cells (src, ras, and mos) is suppressed by radicicol and it also disrupts the K-Ras-activated signaling pathways by selective depletion of Raf kinase.7,8 In addition, it also exhibits anti-angiogenic activity in vivo, and reduces the expression of VEGF.9,10
Radicicol inhibits AP-1-, NF-kB- and serum response factor (SRF)-mediated transcription.11 It inhibits the expression of COX-2 without affecting COX-1 expression in LPS-stimulated macrophages,1 and induces the differentiation of HL-60 cells into macrophages, by blocking the cell cycle at G1 and G2 sites.12
Lyophilized Powder
Radicicol (#R-370) is a highly pure, natural, and biologically active compound.
For research purposes only, not for human use
Last Update: 07/05/2024
Applications
Citations
Citations
Powered by Bioz
